Variant
IDH2 R140
CI-VAR-00003664Explore in graph →ClinVar 375988 CIViC 62
Curated evidence
Evidence by cancer (6 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22616558
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia4 | ||||||||
| IDH2 R140 | (prognostic) | Prognostic | B | Does Not Support N/A | 2 | accepted | EID327In this meta-analysis of adult non-promyelocytic AML (11 studies), patients with IDH2 R140 or R172 mutations had event free survival and overall survival similar to those with wild-type IDH2. PMID 22616558 · Zhou et al., 2012 · Open in CIViC | civic |
| IDH2 R140 | (prognostic) | Prognostic | B | Supports Better Outcome | 3 | accepted | EID350In AML, patients with IDH2 R140 mutation have improved overall survival compared to those with wild-type IDH2. PMID 21596855 · Green et al., 2011 · Open in CIViC | civic |
| IDH2 R140 | (prognostic) | Prognostic | ||||||
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available